Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that encore data from a Phase 2a, proof-of-concept study of GBR 830, an investigational treatment in development for moderate-to-severe atopic dermatitis (AD), will be presented at the Fall Clinical Dermatology Conference in Las Vegas.

The poster, GBR 830 induces progressive and sustained improvements in atopic dermatitis skin biomarkers and clinical parameters, describes findings from this exploratory study, including evaluation of safety and the effect of the investigational drug on AD biomarkers, and provides the first clinical evidence of biological activity.

''Presentation of these data from a Phase 2a study of our lead biologic candidate, GBR 830, along with detailed ex vivo studies that elucidate its mechanism, is part of our continued commitment to further analyze and characterize the unique profile and activity of this potential treatment for atopic dermatitis,'' said Mahboob Rahman, President and Chief Medical Officer at Glenmark Pharmaceuticals. ''We look forward to sharing further updates in the future, as the current and ongoing Phase 2b trial of GBR 830 progresses.'' 

Shares of the company declined Rs 3.1, or 0.52%, to trade at Rs 596.90. The total volume of shares traded was 8,314 at the BSE (9.46 a.m., Friday).